Cocrystal Pharma, Inc. (COCP)

Nasdaq: COCP · Pharmaceutical Preparations · Bothell, WA · filing with the SEC since 2007

Full chart Alerts Compare

Grade5.1

◀ Past 5.3● Present 3.9▶ Future 6.0

5 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Cocrystal Pharma, Inc.

Nine metrics read from its own filings, by tense

Headline grade

5.1/10

◀ Past5.325% of the headline

● Present3.935% of the headline

▶ Future6.040% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 4 read as filed from the record and 5 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.3/1025% of the headline grade · 1 of 3 filed, 2 estimated

Surviving crises

as filed

4.1/10

Has it survived what it has been through?

9 warning events since 2017; the latest 2022-10-26.

weight 22% of this tense · 41st percentile among 497 sector filers · read for itself

From the record

Cocrystal Pharma, Inc.'s filings since 2017 show 9 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2022-10-26); an auditor change (8-K item 4.01, the latest 2019-04-18); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2019-03-19) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

SI estimate

5.1/10

What has it actually done, year after year?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 324 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one.
What the record cannot read: Fewer than three filed years of revenue on file.
How it was reasoned: family median, 324 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cocrystal Pharma, Inc.'s track record is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Shareholder treatment

SI estimate

6.2/10

How has it treated the people who own it?

SI estimate 6.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 62nd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 38% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cocrystal Pharma, Inc.'s shareholder treatment is put at 6.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 38% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.9/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

4.5/10

Is it financially healthy right now?

ROE -139%: lost 139¢ per shareholder dollar. Leverage 35%: owes 35¢ per asset dollar.

weight 45% of this tense · 45th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Cocrystal Pharma, Inc. lost about 139 cents for every dollar of shareholders' money. Leverage: it owed about 35 cents per dollar of assets, and net share issuance: its share count grew 11.0% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 49% of its family
return on equitybottom 25% of its family
the share count against the year beforetop 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

2.4/10

How strong is its position in its industry?

bottom 23% of 315 in its family; net margin -479%.

weight 22% of this tense · 23rd percentile among 315 sector filers · read for its customers

From the record

Cocrystal Pharma, Inc.'s standing among 315 graded names in its industry family: revenue of $2 million in fiscal 2020 ranks in the bottom 28% by size; a net margin of -479% ranks in the bottom 38%; revenue growth of -69.2% a year over the last 1 filed years ranks in the bottom 4% (its annual reports).

What it rests on

revenue against the family$2.0Mbottom 28% of its family
net margin-479.0%bottom 38% of its family
three-year revenue growth-69.2%bottom 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

4.2/10

What are the people in charge doing?

bottom 42% of 315 in its family for leadership; chief executive since 2026.

weight 33% of this tense · 42nd percentile among 315 sector filers · read for its shareholders

From the record

Cocrystal Pharma, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Sapirstein, James (Chief Executive Officer, as filed), filing under that title since 2026-06-03, 5 months (bottom 7% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 8.6 years (top 15%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge6 in three years among 10 peoplebottom 33% of its family
the median years the people in charge have filed8.6 yearstop 15% of its family
the chief executive's years on the record5 monthsbottom 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

6.0/1040% of the headline grade · 0 of 3 filed, 3 estimated

Room to expand

SI estimate

7.8/10

How much room does it have to grow?

SI estimate 7.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 78th percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, cash less debt against assets, which ranks in the top 22% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned: one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cocrystal Pharma, Inc.'s room to expand is put at 7.8 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 22% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

SI estimate

5.0/10

What could actually drive growth from here?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 307 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one.
What the record cannot read: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned: family median, 307 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cocrystal Pharma, Inc.'s growth drivers is put at 5.0 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cocrystal Pharma, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton COCP · research, not advice